Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

WORX vs HSTM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HSTM Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 10–0 Matrix Metrics)

HSTM Overall Winner 6-Pillar Tally: WORX 1 – 4 HSTM (1 Tie) Matrix Metrics: WORX 0 – 10 HSTM

As of Nov 16, 2026, HealthStream Inc (HSTM) is the stronger overall head-to-head candidate over SC WORX Corp (WORX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WORX carries a Unified Composite Score of 34.1/100 (SELL) at $1.15 (N/M Forward P/E, -20.1% operating margin), whereas HSTM carries 55.8/100 (HOLD) at $27.68 (30.1x Forward P/E, 7.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About WORX vs HSTM
WORX NASDAQ
SC WORX Corp
Services-Computer Processing & Data Preparation
$1.15
-6.5% 1D
Market Cap $1.7M
TTM Revenue $2.9M
Forward P/E N/M
Beta / 30D Vol 23.01β · 208% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 15.0 Fund 31.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.8% over 20 days), RSI 71
RSI-14: 71.4 · SMA20: $0.24 · SMA50: $0.24
HSTM NASDAQ Head-to-Head Winner
HealthStream Inc
Services-Computer Programming, Data Processing, Etc.
$27.68
-1.04% 1D
Market Cap $855.8M
TTM Revenue $328M
Forward P/E 30.1x
Beta / 30D Vol 0.39β · 48% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 45.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 28
RSI-14: 28.5 · SMA20: $31.74 · SMA50: $31.07

6-Pillar Scorecard Institutional Category Breakdown (WORX 1 – 4 HSTM)

Columns: Metric · WORX · HSTM
1. Valuation Multiples HSTM
Forward P/E N/M 30.1x
Trailing P/E N/M 40.0x
PEG Ratio N/M 2.95x
EV / Revenue 0.6x 2.6x
2. Growth & Scale HSTM
Revenue Growth (YoY) +3.4% +8.9%
Earnings Growth (YoY) +0.0% -10.0%
TTM Revenue (USD) $2.9M $328M
Market Cap $1.7M $855.8M
3. Profitability & Quality HSTM
Gross Margin 44.7% 64.7%
Operating Margin -20.1% 7.8%
Net Profit Margin -80.5% 6.2%
Return on Equity (ROE) -38.1% 5.5%
4. Balance Sheet & Cash Flow HSTM
Cash Generation (TTM) -$914,262 $45M EBITDA
Cash Flow Margin -31.2% 13.6% EBITDA Mgn
Net Cash / Leverage $77.66 Book/Sh · -38.1% ROE $13.13 Book/Sh · 5.5% ROE
Dividend Yield None (0.00%) 0.48%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 21.1% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat WORX
OpEx & R&D Intensity 64.8% of Rev ($1.9M) 56.9% of Rev ($187M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: WORX (0) vs HSTM (10)
Institutional Metric WORX HSTM Criterion Row Edge
Market Capitalization
Scale
$1.7M $855.8M Larger Scale HSTM
Trailing P/E Ratio
Valuation
N/M 40.0x Lower Multiple HSTM
Forward P/E Ratio
Valuation
N/M 30.1x Lower Multiple HSTM
Revenue Growth (YoY)
Growth
+3.4% +8.9% Higher Growth HSTM
Operating Margin (TTM)
Profitability
-20.1% 7.8% Higher Margin HSTM
Net Profit Margin
Profitability
-80.5% 6.2% Higher Margin HSTM
Return on Equity (ROE)
Capital Efficiency
-38.1% 5.5% Higher ROE HSTM
52-Week Range Position
Momentum
17% ($0–$6) 51% ($20–$36) Stronger Trend HSTM
Beta / 30D Volatility
Risk Regime
23.01β · 208% Vol 0.39β · 48% Vol Lower Realized Risk HSTM
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 55.8 / 100 (HOLD) Higher Composite HSTM
Trailing 12M Revenue (USD)
Operating Scale
$2.9M $328M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.7% 64.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.6x EV/Rev 2.95x PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$914,262 ($77.66 Book/Sh · -38.1% ROE) $45M EBITDA ($13.13 Book/Sh · 5.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HSTM +0.22 pp
WORX: -16.67% · HSTM: -16.45%
3M Horizon WORX +198.06 pp
WORX: +228.38% · HSTM: +30.32%
6M Horizon WORX +314.92 pp
WORX: +327.35% · HSTM: +12.43%
1Y Horizon WORX +250.12 pp
WORX: +262.78% · HSTM: +12.66%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on WORX vs HSTM. Trailing 12-month operating profitability (WORX -20.1% vs HSTM 7.8%) and valuation multiples (WORX N/M vs HSTM 30.1x Forward P/E) are benchmarked directly in Pillar 4 below.

WORX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.9M
Gross Margin44.7%
Op. Margin-20.1%
ROE / Fwd P/E-38.1% · N/M
HSTM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$328M
Gross Margin64.7%
Op. Margin7.8%
ROE / Fwd P/E5.5% · 30.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
WORX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WORX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HSTM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 21.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HSTM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
WORX Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $1.7M market capitalization and -20.1% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($1.9M)
90D Engineering Disclosures 0 Published
HSTM Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $855.8M market capitalization and 7.8% operating margin.
OpEx & R&D Reinvestment 56.9% of Rev ($187M)
90D Engineering Disclosures 0 Published

Investor FAQ WORX vs HSTM Key Questions & Quantitative Answers

As of Nov 16, 2026, HealthStream Inc (HSTM) is the stronger overall head-to-head candidate over SC WORX Corp (WORX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WORX carries a Unified Composite Score of 34.1/100 (SELL) at $1.15 (N/M Forward P/E, -20.1% operating margin), whereas HSTM carries 55.8/100 (HOLD) at $27.68 (30.1x Forward P/E, 7.8% operating margin). Technically, WORX sits in a Markup phase (RSI 71.4, UNCLASSIFIED options structure) and HSTM sits in a Neutral phase (RSI 28.5, UNCLASSIFIED options structure).

HSTM leads the Growth & Scale pillar: WORX posts +3.4% YoY revenue growth and +0.0% YoY earnings growth on $2.9M TTM revenue (44.7% gross margin, -20.1% operating margin), compared with HSTM at +8.9% YoY revenue growth and -10.0% YoY earnings growth on $328M TTM revenue (64.7% gross margin, 7.8% operating margin). On trailing 12-month operating scale, WORX generates $2.9M in USD-normalized revenue versus $328M for HSTM. In operating R&D and SG&A reinvestment, WORX deploys 64.8% of Rev ($1.9M) (0 90-day corporate R&D disclosures) versus 56.9% of Rev ($187M) (0 disclosures) for HSTM.

HSTM screens cheaper on headline valuation multiples. WORX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-31.2% FCF margin), whereas HSTM trades at 30.1x Forward P/E, 40.0x Trailing P/E, 2.95x PEG, and 2.6x EV/Revenue (13.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WORX (-38.1% ROE) versus HSTM (5.5% ROE) capital efficiency.

In options market volatility and institutional positioning, WORX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (23.01β · 208% Vol realized risk). By comparison, HSTM carries 21.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.